(Q33858807)

29 July 2017

2 references

29 May 2020

23 December 2020

1 reference

systematic review

1 reference

title

Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis (English)

1 reference

29 July 2017

2 references

29 May 2020

23 December 2020

2 references

23 December 2020

1 reference

1 reference

1 reference

Adolfo J O Scherr

1

1 reference

29 July 2017

Joao Paulo S N Lima

2

1 reference

29 July 2017

Emma C Sasse

3

1 reference

29 July 2017

Carmen S P Lima

4

1 reference

29 July 2017

André D Sasse

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

31 March 2011

6 references

29 July 2017

3 April 2019

20 June 2019

25 June 2019

29 May 2020

23 December 2020

5 references

29 July 2017

3 April 2019

20 June 2019

25 June 2019

23 December 2020

11

1 reference

29 July 2017

page(s)

115

1 reference

Creative Commons Attribution 2.0 Generic

29 July 2017

copyright license

5 references

3 April 2019

20 June 2019

25 June 2019

29 May 2020

on focus list of Wikimedia project

23 December 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

5 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Practical methods for incorporating summary time-to-event data into meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Adjuvant therapy for renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Measuring inconsistency in meta-analyses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Meta-analysis in clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080342

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-11-115

Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study

21 January 2018

1 reference

12 December 2020

Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group

1 reference

12 December 2020

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

12 December 2020

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

1 reference

12 December 2020

Renal cell carcinoma: survival and prognostic factors

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-115

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference